Archive for the 'Peritoneal (Abdominal Mesothelioma)' Category
Malignant peritoneal mesothelioma; cancer of the lining of the abdominal caviety.
April 29th, 2008. Malignant peritoneal mesothelioma as a rare cause of ascites: a case report
Conclusion: We concluded from this case that Peritoneal Mesothelioma although rare but should be considered among the differential diagnosis of Ascites.
April 16th, 2008. Mortality from pleural and peritoneal cancer in a cohort of asbestos workers, many years after start of the exposure: possible role of fibers clearance]
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
April 16th, 2008. Activity of the Campania Register of Mesothelioma from july 2003 to October 2007
16%), Ship building (7. 5%).
Posted in Causation, Epidemiological, Full Archive, General, Occupational Asbestos Exposure, Pericardial, Peritoneal (Abdominal Mesothelioma), Pleural, Tunica Vaginalis Testis, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 15th, 2008. A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma
In addition, Gascintigraphy and FDG-PET are useful auxiliary diagnostic tools. In the future, we hope to differentiate epithelial, sarcomatous and biphasic types based on imaging findings.
April 10th, 2008. Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusion: Definitive eradication by means of cytoreduction and HIPEC seems a safe and effective therapeutic option for MPM.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 21st, 2008. Pericardial tumors
Primary tumors of the pericardium are extremely rare and occur in a broad age range. This review describes several of the more common lesions: germ cell tumors, solitary fibroma, pericardial mesothelioma, and metastatic disease.
March 20th, 2008. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation
This unusual group of tumors is linked together by a common site of origin and imaging manifestations that mimic those of peritoneal carcinomatosis. Knowledge of the spectrum of imaging findings in this group of primary peritoneal tumors, along with their clinical and pathologic characteristics, is important in the evaluation of patients with diffuse peritoneal disease.
February 26th, 2008. Malignant peritoneal mesothelioma tumours. Evolution, treatment, prognosis
The diagnosis of peritoneal mesothelioma is often delayed, in part because of the usually long latent period (peaking at 40-45 years from the time of initial exposure to asbestos) and because the common presenting symptoms of weight loss, usually with a full abdomen, malaise, and abdominal discomfort, are mild and nonspecific. This paper aim is to present a case report regarding a patient diagnosed with malignant peritoneal mesothelioma with an unpredictable evolution.
January 31st, 2008. Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications
Last big published series results show a decrease of morbidity and mortality and interest of using new drugs like oxaliplatine. Indications have to be more homogeneous and based on evidences.
January 29th, 2008. Long-term results of peritonectomy on the patients with peritoneal carcinomatosis
Peritonectomy is recommended for patients with PMP, AC and colorectal cancer. In gastric cancer, it is indicated for patients with PCI less than 14.
January 9th, 2008. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
Conclusions: IPHP is a safe treatment modality for patients with peritoneal carcinomatosis. It has an acceptable complications rate and ensures a marked improvement in survival and in the quality of life in selected patients.
January 9th, 2008. Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: A case report
Routine cytology supported by three adjuvant methods enabled us to correctly establish the diagnosis. Our case suggests that a cytological diagnosis of malignant mesothelioma supported by adjuvant methods should not be rejected even if based on negative histological results.
January 2nd, 2008. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy
Conclusion: This new approach combining complete cytoreductive surgery considerably increases the survival of patients with MPM compared with the standard treatment based on systemic chemotherapy.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Oxaliplatin (Eloxatin), Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 22nd, 2007. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions
Conclusions: Anti-L523S antibody is a useful marker for the detection of malignant cells in serous effusions and it can have significant utility in differentiating reactive mesothelial cells from malignant mesothelioma and metastatic carcinoma in combination with calretinin and CK5/6 staining.
December 21st, 2007. Updated treatment of peritoneal carcinomas: a review
Considering the constant increasing of diseases treatable with this procedure, more centres should be activated. The establishment of a clear policy and scientific guidelines is mandatory, in order to perform the CRS+HIPEC safely, minimizing treatment-related morbidity and mortality and maximizing the results in terms of survival and quality of life.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 17th, 2007. Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center
Conclusions: In a high-volume center with extensive experience treating peritoneal malignancies, perioperative mortality can be lowered to nearly zero, although morbidity remains high. CS-HIPEC procedures should be studied further in a controlled manner to help define their important role in the care of patients with PC.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 7th, 2007. Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
Conclusion: Postoperative morbidity is dependent mainly on a tumor type; however, the chemotherapeutic agent used might also influence morbidity. Survival is determined by optimal cytoreduction and tumor type. Irrespective of age, patients with good performance status benefit from this treatment.
November 23rd, 2007. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma
Conclusion: Our results show for the first time that survivin, as well as other IAPs, is largely expressed in clinical MPMs and suggest that strategies aimed at down-regulating survivin may provide a novel approach for the treatment of the malignancy.
November 22nd, 2007. Pathologic and anatomic evidence of peritoneal metastases
Primary tumours originating in the peritoneum such as malignant peritoneal mesothelioma, primary peritoneal carcinoma, and benign peritoneal tumours along with inflammatory and reactive lesions must be differentiated from peritoneal metastases. Especially in cancer of unknown primary tumour, the discrimination between primary peritoneal tumours and peritoneal metastases is difficult and often requires immunhistochemical identification.
|
|  |
